FY2026 Q2 Financial Results Presentation

from the beginning

FY2026 Q2 Financial Results Presentation

Forward-Looking Statements

1 FY2026 Q2 Financial Results

Overview

Overview of FY2026 Q2 Results

Revenue

Operating Profit

Profit Attributable to Owners of the Company

Following the Correction to FY2025 Financial Results

Progress on Operational Excellence

2 Business Update

Performance

Performance

New Collaboration with Summit Therapeutics

New Commercialization Unit

3 R&D Update

Expand Enhertu into 1L HER2 mutant NSCLC

Regulatory Updates for Indication Expansion

Updates for Indication Expansion and Regulatory Review

Updated Analysis of Patients with Platinum-Resistant Ovarian Cancer

Expand DXd ADCs to Address Broad Spectrum of Ovarian Cancers

FY2026 News Flow

Upcoming IR Event: Sustainability Meeting

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10

• Q&A 11

• Q&A 12